Compare Innoviva, Inc. (INVA) vs Eli Lilly and Company (LLY) Stock

Innoviva, Inc. (INVA) offers the better valuation at 6.9x trailing P/E (11.5x forward), making it the more compelling value choice. Analysts rate Innoviva, Inc. (INVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc. (INVA) is the cheapest at 6.9x versus Eli Lilly and Company at 85.7x. On forward P/E, Innoviva, Inc. is actually cheaper at 11.5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 1.12x versus Eli Lilly and Company's 4.79x — a reasonable growth-adjusted valuation.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +396.9%, compared to +97.5% for Innoviva, Inc. (INVA). A $10,000 investment in LLY five years ago would be worth approximately $50K today (assuming dividends reinvested). Over 10 years, the gap is even starker: LLY returned +1316% versus INVA's +81.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc. (INVA) is the lower-risk stock at 0.07β versus Eli Lilly and Company's 0.65β — meaning LLY is approximately 825% more volatile than INVA relative to the S&P 500.

Innoviva, Inc. (INVA) is the more profitable company, earning 63.8% net margin versus 23.5% for Eli Lilly and Company — meaning it keeps 63.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 38.9% versus 38.5% for INVA. At the gross margin level — before operating expenses — LLY leads at 81.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 1.12x versus Eli Lilly and Company's 4.79x. A PEG below 1.5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11.5x forward P/E versus 29.4x for Eli Lilly and Company — 17.9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 43.0% to $32.50.

In this comparison, LLY (0.5% yield) pays a dividend. INVA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.65), 0.5% yield, +1316% 10Y return). Both have compounded well over 10 years (LLY: +1316%, INVA: +81.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: INVA is a small-cap deep-value stock; LLY is a large-cap quality compounder stock. LLY pays a dividend while INVA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.